193 related articles for article (PubMed ID: 32776710)
1. Aberrant glycosylation patterns on cancer cells: Therapeutic opportunities for glycodendrimers/metallodendrimers oncology.
Moffett S; Shiao TC; Mousavifar L; Mignani S; Roy R
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jan; 13(1):e1659. PubMed ID: 32776710
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of carbohydrate-based polymeric and nanoparticle systems.
Sunasee R; Adokoh CK; Darkwa J; Narain R
Expert Opin Drug Deliv; 2014 Jun; 11(6):867-84. PubMed ID: 24666000
[TBL] [Abstract][Full Text] [Related]
3. Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response.
Rawding PA; Bu J; Wang J; Kim DW; Drelich AJ; Kim Y; Hong S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Mar; 14(2):e1752. PubMed ID: 34414690
[TBL] [Abstract][Full Text] [Related]
4. Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation.
Guo S; Xu C; Yin H; Hill J; Pi F; Guo P
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1582. PubMed ID: 31456362
[TBL] [Abstract][Full Text] [Related]
5. Understanding the mechanisms of silica nanoparticles for nanomedicine.
Li Z; Mu Y; Peng C; Lavin MF; Shao H; Du Z
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jan; 13(1):e1658. PubMed ID: 32602269
[TBL] [Abstract][Full Text] [Related]
6. Embracing nanomaterials' interactions with the innate immune system.
Teunissen AJP; Burnett ME; Prévot G; Klein ED; Bivona D; Mulder WJM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Nov; 13(6):e1719. PubMed ID: 33847441
[TBL] [Abstract][Full Text] [Related]
7. Biogenic nanoparticles as immunomodulator for tumor treatment.
Cheng K; Kang Q; Zhao X
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Nov; 12(6):e1646. PubMed ID: 32464709
[TBL] [Abstract][Full Text] [Related]
8. Targeting the "Sweet Side" of Tumor with Glycan-Binding Molecules Conjugated-Nanoparticles: Implications in Cancer Therapy and Diagnosis.
Bloise N; Okkeh M; Restivo E; Della Pina C; Visai L
Nanomaterials (Basel); 2021 Jan; 11(2):. PubMed ID: 33499388
[TBL] [Abstract][Full Text] [Related]
9. Bridging Bio-Nano Science and Cancer Nanomedicine.
Björnmalm M; Thurecht KJ; Michael M; Scott AM; Caruso F
ACS Nano; 2017 Oct; 11(10):9594-9613. PubMed ID: 28926225
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of glycodendrimers.
Turnbull WB; Stoddart JF
J Biotechnol; 2002 May; 90(3-4):231-55. PubMed ID: 12071227
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology platforms for cancer immunotherapy.
Yang Z; Ma Y; Zhao H; Yuan Y; Kim BYS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1590. PubMed ID: 31696664
[TBL] [Abstract][Full Text] [Related]
12. Glyconanoparticles polyvalent tools to study carbohydrate-based interactions.
Marradi M; Martín-Lomas M; Penadés S
Adv Carbohydr Chem Biochem; 2010; 64():211-90. PubMed ID: 20837200
[TBL] [Abstract][Full Text] [Related]
13. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
14. Multivalent glyco(cyclo)peptides.
Galan MC; Dumy P; Renaudet O
Chem Soc Rev; 2013 Jun; 42(11):4599-612. PubMed ID: 23263159
[TBL] [Abstract][Full Text] [Related]
15. Stimuli-activatable nanomedicines for chemodynamic therapy of cancer.
Wang W; Jin Y; Xu Z; Liu X; Bajwa SZ; Khan WS; Yu H
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1614. PubMed ID: 32011108
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicine: a new frontier in cancer therapeutics.
Lee PY; Wong KK
Curr Drug Deliv; 2011 May; 8(3):245-53. PubMed ID: 21291378
[TBL] [Abstract][Full Text] [Related]
17. Emerging methods in therapeutics using multifunctional nanoparticles.
Habibi N; Quevedo DF; Gregory JV; Lahann J
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1625. PubMed ID: 32196991
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
19. Targeting C-type lectin receptors with multivalent carbohydrate ligands.
Lepenies B; Lee J; Sonkaria S
Adv Drug Deliv Rev; 2013 Aug; 65(9):1271-81. PubMed ID: 23727341
[TBL] [Abstract][Full Text] [Related]
20. Multi-dimensional glycan microarrays with glyco-macroligands.
Narla SN; Nie H; Li Y; Sun XL
Glycoconj J; 2015 Oct; 32(7):483-95. PubMed ID: 25957565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
